Updating results

568 results

Sort: Relevance | Date

Rehabilitation in adults with complex psychosis and related severe mental health conditions

In development [GID-NG10092] Expected publication date: 19 June 2020

NICE guideline In development

Social, emotional and mental wellbeing in primary and secondary education

In development [GID-NG10125] Expected publication date: 28 May 2021

NICE guideline In development

Vaccine uptake in the general population

In development [GID-NG10139] Expected publication date: 19 October 2021

NICE guideline In development

Workplace health: long-term sickness absence and capability to work (Update)

In development [GID-NG10090] Expected publication date: 20 November 2019

NICE guideline In development

Social work interventions for adults with complex needs, including, learning disabilities and mental health

In development [GID-NG10145] Expected publication date: 19 January 2022

NICE guideline In development

Cannabidiol for adjuvant treatment of seizures associated with Dravet syndrome [ID1211]

In development [GID-TA10274] Expected publication date: 18 December 2019

Technology appraisal guidance In development

Cannabidiol for adjuvant treatment of seizures associated with Lennox-Gastaut syndrome [ID1308]

In development [GID-TA10410] Expected publication date: 18 December 2019

Technology appraisal guidance In development

Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]

In development [GID-TA10534] Expected publication date: TBC

Technology appraisal guidance In development

Decision-making and mental capacity

In development [GID-QS10127] Expected publication date: 31 March 2020

Quality standard In development

Renal stones

In development [GID-QS10095] Expected publication date: 16 April 2020

Quality standard In development

ERC1671 for treating progressed or recurrent glioblastoma ID1623

In development [GID-TA10489] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (update)

In development [GID-QS10132] Expected publication date: 13 December 2019

Quality standard In development

Heavy menstrual bleeding (QS update)

In development [GID-QS10134] Expected publication date: 23 June 2020

Quality standard In development

Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

In development [GID-TA10418] Expected publication date: TBC

Technology appraisal guidance In development

SEM Scanner 200 for pressure ulcer prevention

In development [GID-MT533] Expected publication date: 06 July 2020

Medical technologies guidance In development

Diabetes update

In development [GID-NG10152] Expected publication date: TBC

NICE guideline In development

Rivaroxaban for preventing major cardiovascular events in people with coronary or peripheral artery disease [ID1397]

In development [GID-TA10347] Expected publication date: TBC

Technology appraisal guidance In development

Safeguarding adults in care homes

In development [GID-NG10107] Expected publication date: 21 October 2020

NICE guideline In development

Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management

In development [GID-NG10091] Expected publication date: 14 October 2020

NICE guideline In development

Asthma: diagnosis, monitoring and chronic asthma management

In development [GID-NG10143] Expected publication date: 29 January 2020

NICE guideline In development

Danis Stent for acute oesophageal variceal bleeds

In development [GID-MT537] Expected publication date: 07 July 2020

Medical technologies guidance In development

Babies, children and young people's experience of healthcare

In development [GID-NG10119] Expected publication date: 07 April 2021

NICE guideline In development

Shared decision making

In development [GID-NG10120] Expected publication date: 14 April 2021

NICE guideline In development

Acute coronary syndromes

In development [GID-NG10085] Expected publication date: 25 June 2020

NICE guideline In development

Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

In development [GID-TA10429] Expected publication date: TBC

Technology appraisal guidance In development

Lanadelumab for preventing recurrent attacks of hereditary angioedema [ID1268]

In development [GID-TA10333] Expected publication date: 16 October 2019

Technology appraisal guidance In development

Abortion care

In development [GID-QS10084] Expected publication date: 18 August 2020

Quality standard In development

Reducing sexually transmitted infections

In development [GID-NG10142] Expected publication date: 01 September 2021

NICE guideline In development

Meningitis (bacterial) and meningococcal septicaemia: recognition, diagnosis and management

In development [GID-NG10149] Expected publication date: 17 February 2022

NICE guideline In development

Multiple sclerosis in adults: management

In development [GID-NG10153] Expected publication date: 27 April 2022

NICE guideline In development

Self-harm in over 8s: short- and long-term management and prevention of recurrence

In development [GID-NG10148] Expected publication date: 26 January 2022

NICE guideline In development

Depression in adults: treatment and management

In development [GID-CGWAVE0725] Expected publication date: TBC

NICE guideline In development

Skin tumours including Melanoma: assessment and management

In development [GID-NG10155] Expected publication date: 28 March 2022

NICE guideline In development

Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]

In development [GID-TA10473] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]

In development [GID-TA10474] Expected publication date: TBC

Technology appraisal guidance In development

Sapropterin for treating phenylketonuria [ID1475]

In development [GID-TA10378] Expected publication date: TBC

Technology appraisal guidance In development

Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma ID997

In development [GID-TA10382] Expected publication date: TBC

Technology appraisal guidance In development

Avelumab for previously treated platinum-resistant ovarian cancer ID1497

In development [GID-TA10404] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer [ID1513]

In development [GID-TA10419] Expected publication date: TBC

Technology appraisal guidance In development

Apalutamide for treating metastatic hormone-sensitive prostate cancer [ID1534]

In development [GID-TA10423] Expected publication date: TBC

Technology appraisal guidance In development

L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

In development [GID-TA10452] Expected publication date: TBC

Technology appraisal guidance In development

Seven day working

In development [GID-QS10108] Expected publication date: TBC

Quality standard In development

Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565

In development [GID-TA10502] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab with epacadostat for untreated malignant melanoma ID1423

In development [GID-TA10330] Expected publication date: TBC

Technology appraisal guidance In development

Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147

In development [GID-TA10343] Expected publication date: TBC

Technology appraisal guidance In development

Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab ID1487

In development [GID-TA10437] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with radiation therapy for untreated glioblastoma ID1562

In development [GID-TA10443] Expected publication date: TBC

Technology appraisal guidance In development

Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)

In development [GID-TA10337] Expected publication date: 19 February 2020

Technology appraisal guidance In development

Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy ID1347

In development [GID-TA10264] Expected publication date: TBC

Technology appraisal guidance In development